Research/Areas of Interest: Epstein Barr virus (EBV) is highly prevalent, infecting over 95% of adults worldwide. It is the causative agent of mononucleosis and has strong associations with multiple sclerosis and approximately 200,000 cancer cases annually. EBV+ Burkitt lymphoma (BL) is the leading childhood cancer in Africa, and EBV contributes to HIV-associated BL, Hodgkin lymphoma, post-transplant lymphomas, nasopharyngeal and gastric carcinoma. The lack of specificity and side effects associated with current EBV+ cancer therapies underscore the necessity of our long-term research, which aims to pave the way for the development of novel treatments targeting EBV-driven metabolic vulnerabilities, enhancing effectiveness, and reducing adverse effects. To achieve this, our group employs a diverse range of cutting-edge techniques encompassing molecular biology, transcriptomics, metabolomics, epigenetics, and genome-wide CRISPR/Cas9 screening. By integrating these approaches, we are currently addressing three critical questions: 1. How EBV subverts methyl group metabolic pathways, leading to increased genome hypermethylation, which promotes viral latency and silences tumor suppressors (Check out our recent publication-PMID: 36070681); 2. How EBV generates specialized mitochondria that drive bioenergetic and biosynthetic pathways to fuel the building blocks for cell growth transformation; 3. How EBV orchestrates triglyceride storage and hydrolysis to facilitate B- and epithelial cell transformation.

Education

  • Doctor of Philosophy, Kansas State University, USA, 2018
  • Master of Science, Yangzhou University, CHN, 2013
  • Bachelor of Science, Yangzhou University, CHN, 2010